MTM: MDA Funds Development of Myotubularin-Based Treatment

June, 2013

Valerion Therapeutics (formerly 4s3 Bioscience), with support from MDA, will continue testing its experimental myotubularin-based compound in mice and will begin producing a pharmaceutical-grade compound.

The compound, 3E10FV-MTM1, has shown benefit in myotubularin-deficient mice with a disorder mimicking human MTM.